Search results
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
Reuters via Yahoo News· 1 year agoU.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy...
Health Care Roundup: Market Talk
The Wall Street Journal· 2 hours agoNEWSPLUS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1515 ET...
Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda
The Wall Street Journal· 1 month agoShares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 1 month agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Patients seek relief from spiraling drug prices. Will the Inflation Reduction Act deliver?
USA TODAY via Yahoo News· 2 years agoJackie Trapp has incurable blood cancer and takes a chemotherapy drug that cost more than $240,000...
Patients with incurable cervical cancer to be offered life-extending drug
The Independent UK via AOL· 1 year agoPatients with incurable cervical cancer are to be offered a new treatment which could give them more...
Merck Scores Major Drug Approval, Easing Pain From Keytruda Patent Expiration
Barrons.com· 2 months agoMerck secured Food and Drug Administration approval for a drug widely expected to be an era-defining...
Merck scraps third prostate cancer study as Keytruda therapy disappoints
Reuters via Yahoo News· 1 year agoMerck & Co on Tuesday scrapped a late-stage trial of a combination therapy with its cancer drug...
New drug for cervical cancer patients approved for use in NHS in Scotland
Press Association News via AOL· 1 year agoScotland has become the the first part of the UK to make a new treatment for women with advanced...
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Investor's Business Daily· 5 months agoMerck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the...